NCT01286896 2025-07-10
Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
The Netherlands Cancer Institute
Phase 1 Completed
Clinical Trials
10 trialsNCT02058901 2019-07-17
Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.
Amsterdam UMC, location VUmc
Phase 1 Completed
NCT00861419 2017-02-08
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
Amgen
Phase 1 Completed
NCT00884676 2015-10-09
Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors
University of Miami
Phase 1 Completed
NCT00720148 2014-08-26
A Phase I Trial of Bortezomib and Sunitinib
Emory University
Phase 1 Completed
NCT00729833 2014-06-09
Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT00357318 2014-02-24
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00387920 2014-01-28
Sunitinib in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00495872 2012-10-18
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00528619 2011-04-08
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed